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Conclwon: Moderate H facilitates transthoracic defibrillation. Since TTI rose and current 
fell during H, the improved shock success must be due to a hypothermia-induced change 






1073-93 Performance of an Automated External Cardioverter 
Defibrillator for In-Hospital Ventricular Malignant 
Arrhythmia 
Seroio Timerman, Andre M. Bento, Luiz F. Cardoso, Miguel A. Moretti, Nabil E. Sanadl, 
Jose A. Ramires. Heart Institute (InCor) University of Sao Paula Medical School, Sao 
Paula, Brazil 
Purpose: Ventricular fibrillation (VF) and ventricular tachycardia (VT) are the major 
underlying rhythm during in-hospital cardiac arrest. For a patient in VFNT the probability 
of successful defibrillation and subsequent suwival to hospital discharge is directly and 
negatively related to the time interval between onset of the arrhythmia and delivery of the 
first shock. The data about this interval in clinical practice is heterogeneous and ~nconclu- 
sive, however the literature estimates it to be about 60 seconds in monitored units. Con- 
tinuos ECG monitoring allows identification of such arrhythmias and alert nursmg and 
medical staff. The time delay between the arrhyihmlc event and human intervention is 
still a challenge for clinical practice. 
Methods: We reported the use of an automated external cardioverter defibrillator (AECD) 
in 45 patients considered to be at higher risk for malIgnant arrhythmia for 24 to 48 hours. 
The inclusion criteria was acute coronary syndrome, cardiogemc shock and previous epi- 
sode of sudden death or malignant ventricular arrhythmia. The exclusion cnteria was the 
use of pacemaker or an implantable cardioverier defibrillator and an R-wave amplitude 
less than 0.7mV peak to peak at themonitor. 
Results: We recorded 17 episodes of VTNF in 3 patients. The median time between the 
beginning of the arrhythmia and the first defibrillation was 33.37 s (range 21 to 65 s). The 
sensibility and specificity were 100%. The success of the defibrillation was 94.11% (16/ 
17) for the first shock and 100% (l/l) for the second shock. There was no adverse event 
during the study penod and no episodes of inappropriate therapy delivery (the detection 
was accurate in all episodes sensitivity 100%). 
Conclusion: AECD was safe and effective. It presents the possibility of providing consis- 
tently rapid identification and response to ventricular malignant arrhyihmla. 
1073-94 The Potential Impact of a Fully Automated External 
Cardioverter Defibrillator in Centrally Monitored 
Hospital Units 
Hew Cusnir, Rohit Tongia. David Kavesteen, Karthik P. Sheka, Frederick Cassera. 
Hannah Scherer, Louise Valeno, Gerald Hollander, Maimonides Medical Center. 
Brooklyn, NY 
Background: Sudden Cardiac Arrest (SCA) survival decreases by 10% for each minute 
of delay in cardioversion, wth survival rates of 96% noted when defibrillation is achieved 
within 30 seconds of collapse. This has led to increasing use of semi-automated external 
defibrillators in many out-of-hospital settings. Recently, a fully automated external cardio- 
verter-defibrillator (AECD) was approved by the FDA for in-hospital use. The AECD can 
be programmed to automatically defibrillate a life threatening ventricular arrhythmia. The 
purpose of this study was to assess the potential impact of in-hospital AECDs on the crit- 
ical time to defibrillation in monitored hospital units. 
Methods: Mock codes (n=l6) were conducted using simulated ventricular fibrillation in 
various monitored units. Observers were stationed to record the time staff responded to 
the arrhythmia, and the time to shock. These times were compared to an AECD protocol 
that automatically defibrillates at an average of 36.3 seconds from onset of arrhythmia 
(ll=l8). 
Results: Staff vs AECD response time to arrhythmia (seconds) was 76.3 f 113.7 (Cl 
19.6 132.6) vs 7.6 f 0.6 (Cl 7.3 7.9). Staff vs AECD time to shock was 169.2 * 103.1 
(Cl 117.9 - 220.4) vs 36.3 * 0.7‘(CI 37.9 - 36.6). p values are < 0.0001 for differences 
between the groups. 
Defibrillation 
Conclusion: AECDs on monitored units could significantly reduce the critical time to 
defibrillation in patients with SCA. We anticipate this would translate to improved survival 
rates, with better neurologlc outcomes. 
1073-95 Immediate Defibrillation Predicts Probability of 
Defibrillation Curve Width for External Defibrillation 
Waveforms 
Oscar H. Tovar, David E. Snyder, Janice L. Jones, VA Medical Center-Georgetown 
University, Washington, DC, Philips Medical Systems, Seattle, WA 
Background: Defibrillation is either immediate (ID) or progressive, i.e. followed by extra- 
systoles before termination, but significance of ID remains unknown. Waveforms having 
large probability of success (POS) curve width are poor for defibrillation because out- 
come is uncertain over a large shock intensity range. We tested the hypothesis that 
waveforms having primarily ID at I50 (current for 50% success) have narrow POS curve 
width. Methods: POS curves were obtained in 21 isolated rabbit hearts using monopha- 
sic damped sine (MDS), and monophasic and biphasic truncated exponential (BTE) 
waveforms with large or small epicardial patches. Fibrillation and defibrillation type were 
recorded usmg monophasic action potential electrodes. Normalized POS curve width, 
defined as (160.120)/150 (NCW), and ID probability at 150 were determined. Results: 
Each waveform/electrode combmation yielded a single point on the nonalized curve 
width YS %ID curve. Probability of ID at I50 ranged from almost 0% for MDS with small 
electrodes to 100% for BTE with large electrodes. Probability of ID at 150 closely corre- 
lated with normalized curve width (R2 = 0.97, figure). Conclusion: The finding that a 
high probability of immediate defibrillation in low regions of the POS curve correlates with 
narrow defibrillation POS curves may lead to improved waveform/ electrode combina- 
tions that will enhance defibrillation success. 
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1074-96 Platelet Glycoprotein Ilb/llla Antagonists Are Beneficial 
in Patients With Acute Coronary Syndromes Who 
Undergo In-Hospital Coronary Artery Bypass Surgery 
Marco Roffi David J. Mollterno, Michael S. Lauer, Joel Reginelli. Gang Jia, Eric J. Topol, 
The Cleveland Clinic Foundation, Cleveland, OH, Unwersity Hospital. Zurich, 
Switzerland 
Background:The use of platelet glycoprotein Ilb/lla receptor antagonists (GP Ilb/llla) in 
non-ST-segmenf elevation acute coronary syndromes (ACS) is widely accepted, espe- 
cially for percutaneous coronary intervention. However, their efficacy in patients under- 
going in-hospital coronary artery bypass grafting (CABG) is not well established. 
Methods: We performed a pooled analysis of 4 large-scale, placebo-controlled, Ilb/llla 
ACS trials, namely PURSUIT, GUSTO IV, PARAGON A, and PARAGON B. and 
addressed outcomes among patients undergoing in-hospital CABG (N=3166) according 
to treatment allocation. Results Reported in the table 
Conclusions: The use of GP Ilb/llla Inhibitors among patients with ACS undergoing in- 
hospital CABG I?. associated with a benefit that persists at 6 months. 
